Pal Mahima, Paliwal Sarvesh
Department of Pharmacy, Banasthali University, Banasthali, Tonk, Rajasthan, India.
Org Med Chem Lett. 2012 Mar 1;2(1):7. doi: 10.1186/2191-2858-2-7.
AT1 receptor antagonists are clinically effective drugs for the treatment of hypertension, cardiovascular, and related disorders. In an attempt to identify new AT1 receptor antagonists, a pharmacophore-based virtual screening protocol was applied. The pharmacophore models were generated from 30 training set compounds. The best model was chosen on the basis of squared correlation coefficient of training set and internal test set. The validity of the developed model was also ensured using catScramble validation method and external test set prediction.
The final model highlighted the importance of hydrogen bond acceptor, hydrophobic aliphatic, hydrophobic, and ring aromatic features. The model satisfied all the statistical criteria such as cost function analysis and correlation coefficient. The result of estimated activity for internal and external test set compounds reveals that the generated model has high prediction capability. The validated pharmacophore model was further used for mining of 56000 compound database (MiniMaybridge). Total 141 hits were obtained and all the hits were checked for druggability, this led to the identification of two active druggable AT1 receptor antagonists with diverse structure.
A highly validated pharmacophore model generated in this study identified two novel druggable AT1 receptor antagonists. The developed model can also be further used for mining of other virtual database.
AT1受体拮抗剂是治疗高血压、心血管疾病及相关病症的临床有效药物。为了寻找新的AT1受体拮抗剂,应用了基于药效团的虚拟筛选方案。药效团模型由30种训练集化合物生成。基于训练集和内部测试集的平方相关系数选择最佳模型。还使用catScramble验证方法和外部测试集预测确保了所开发模型的有效性。
最终模型突出了氢键受体、疏水脂肪族、疏水和芳环特征的重要性。该模型满足所有统计标准,如成本函数分析和相关系数。内部和外部测试集化合物的估计活性结果表明,所生成的模型具有较高的预测能力。经验证的药效团模型进一步用于挖掘56000个化合物数据库(MiniMaybridge)。共获得141个命中结果,并对所有命中结果进行了成药可能性检查,从而鉴定出两种结构不同的活性可成药AT1受体拮抗剂。
本研究生成的经过高度验证的药效团模型鉴定出两种新型可成药AT1受体拮抗剂。所开发的模型还可进一步用于挖掘其他虚拟数据库。